Evotec AG has joined forces with one of the new Johnson & Johnson Inc innovation centres to identify targets for Alzheimer’s disease with a view to discovering and developing potential therapies that could affect early-stage disease. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
